Krsnaa Diagnostics Limited (KRSNAA) Fair Value & Analysis
Healthcare · IN · Market cap ₹18.6B
Fair value as of: Jul 3, 2026
From 16 valuation models · updated yesterday
Share price +4.0% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹529.59 – ₹881.67 · fair‑value band ₹423.68 – ₹757.33 · the ₹572.90 price screens below the ₹582.75 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Krsnaa Diagnostics Limited (KRSNAA) currently trades at ₹572.90, while our model-based Fair Value estimate is ₹582.75 — implying the stock looks roughly 1.7% undervalued today. We read business quality at 42/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Krsnaa Diagnostics Limited generated revenue of ₹8.0B at a net margin of 12.7%. Revenue grew 3.5% year over year. It earns a return on equity of 10.9%. Net debt stands at ₹1.7B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Krsnaa Diagnostics Limited provides diagnostic services in India. It offers a range radiology services, including computed tomography scans, magnetic resonance imaging, X-rays, and ultrasound and advanced imaging; pathology services, such as laboratory, and home collection and preventive health; and teleradiology and telepathology services. The company also provides other diagnostics services, such as ophthalmic test, mammography, dental imaging, stress test, dual-energy X-ray absorptiometry scan, and bone mineral density test. It serves individual patients, government clients, corporate clients, hospitals, clinics, private practitioner, and other healthcare providers. Krsnaa Diagnostics Limited was incorporated in 2010 and is based in Pune, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Krsnaa Diagnostics Limited reported revenue of ₹7.7B in FY2026 versus ₹4.6B in FY2022, a compound +14.1%/yr. Reported net income was ₹1.0B in FY2026, compounding +10.4%/yr from FY2022.
Is KRSNAA fairly valued? → Check now
Similar stocks
6 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $482.04 | $202.02 | -58% |
| Danaher Corporation DHR | $183.63 | $87.65 | -52% |
| WuXi AppTec Co 2359 | HK$152.80 | HK$120.99 | -21% |
| IDEXX Laboratories, Inc IDXX | $545.73 | $255.77 | -53% |
| Lonza Group LZAGY | $61.53 | $15.70 | -74% |
| Agilent Technologies, Inc A | $138.37 | $65.93 | -52% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Krsnaa Diagnostics Limited (KRSNAA) undervalued?
What is the fair value of KRSNAA?
What is the quality score of KRSNAA?
What is the revenue of Krsnaa Diagnostics Limited (KRSNAA)?
What is the net profit margin of KRSNAA?
Does Krsnaa Diagnostics Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.